Related Experiment Video
Updated: May 19, 2026
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
Published on: June 16, 2017
Chromatin modifications as therapeutic targets in MLL-rearranged leukemia
Aniruddha J Deshpande1, James Bradner, Scott A Armstrong
1Division of Hematology/Oncology, Children's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Abstract:
MLL-rearranged leukemias exemplify malignancies with perturbations of the epigenetic landscape. Specific chromatin modifications that aid in the perpetuation of MLL fusion gene driven oncogenic programs are being defined, presenting novel avenues for therapeutic intervention. Proof-of-concept studies have recently been reported, using small-molecule inhibitors targeting the histone methyltransferase disruptor of telomeric silencing 1-like (DOT1L), or the acetyl-histone binding protein bromodomain containing protein 4 (BRD4) showing potent activity against MLL-rearranged leukemias in preclinical models. It is apparent that intensive efforts will be made toward the further development of small-molecule inhibitors targeting these, and other chromatin-associated protein targets. These studies may lead to the advent of a new generation of much-needed therapeutic modalities in leukemia and other cancers.
Insights
Targeting epigenetic regulators like DOT1L and BRD4 shows promise for treating MLL-rearranged leukemias. Further development of these small-molecule inhibitors could lead to new cancer therapies.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- MLL-rearranged leukemias are driven by epigenetic alterations.
- Understanding these chromatin modifications is key for therapeutic strategies.
Purpose of the Study:
- To explore novel therapeutic interventions for MLL-rearranged leukemias.
- To investigate the potential of targeting specific epigenetic regulators.
Main Methods:
- Utilized small-molecule inhibitors targeting DOT1L (disruptor of telomeric silencing 1-like) and BRD4 (bromodomain containing protein 4).
- Evaluated the efficacy of these inhibitors in preclinical models of MLL-rearranged leukemia.
Main Results:
- Inhibitors targeting DOT1L and BRD4 demonstrated potent anti-leukemic activity.
- Proof-of-concept studies confirmed the therapeutic potential of these agents.
Conclusions:
- Targeting epigenetic machinery, specifically DOT1L and BRD4, offers a promising therapeutic avenue for MLL-rearranged leukemias.
- Further development of small-molecule inhibitors against chromatin-associated proteins may yield new cancer treatments.
Related Concept Videos
01:32Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
02:25Spreading of Chromatin Modifications
Writers
The writer is an enzyme that can...
02:32Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...